AMENDMENTS TO THE CLAIMS:

Claim 1. (Currently Amended) A rapidly disintegrating tablet comprising: amoxicillin:

clavulanic acid;

silicified microcrystalline cellulose; and

optionally, one or more excipients,

wherein the tablet includes substantially no <u>disintegrants or</u> superdisintegrants except the silicified microcrystalline cellulose.

Claims 2 – 3. (Cancelled)

Claim 4. (Currently Amended) The rapidly disintegrating tablet according to claim 1, wherein the amoxicillin is in the form of amoxicillin [[20]] trihydrate.

Claim 5. (Previously Presented) The rapidly disintegrating tablet according to claim 1, wherein the clavulanic acid is in the form of potassium clavulanate.

Claim 6. (Previously Presented) The rapidly disintegrating tablet according to claim 1, wherein the ratio of amoxicillin to clavulanic acid is in the range of 2:1 to 30:1.

Claim 7. (Previously Presented) The rapidly disintegrating tablet according to claim 1, wherein the ratio of amoxicillin to clavulanic acid is 4:1.

Claim 8. (Previously Presented) The rapidly disintegrating tablet according to claim 1, wherein the ratio of amoxicillin to clavulanic acid is 7:1.

Claim 9. (Original) The rapidly disintegrating tablet according to claim 1, wherein the proportion of the active substance in the tablet is 5 to 70 % by weight of the tablet.

Claim 10. (Original) The rapidly disintegrating tablet according to claim 1, wherein the ratio of the active substance and silicified microcrystalline cellulose is 0.5:1 to 2.5:1.

Claim 11. (Original) The rapidly disintegrating tablet according to claim 1 wherein the proportion of silicified microcrystalline cellulose is 30 to 95% by weight.

Application No. 10/518,731 October 23, 2009

Claim 12. (Original) The rapidly disintegrating tablet according to claim 1, wherein hydrogenated castor oil is contained as a lubricant.

Claims 13 - 14. (Cancelled)

Claim 15. (Currently Amended) An orodispersible tablet comprising amoxicillin, clavulanic acid and silicified microcrystalline cellulose, wherein the tablet includes substantially no disintegrants or superdisintegrants except the silicified microcrystalline cellulose

Claim 16. (Currently Amended) A dispersible tablet comprising amoxicillin, clavulanic acid and silicified microcrystalline cellulose, wherein the tablet includes substantially no disintegrants or superdisintegrants except the silicified microcrystalline cellulose

Claim 17. (Previously Presented) A process for the manufacture of a rapidly disintegrating tablet according to claim 1 comprising the steps of:

blending the amoxicillin, clavulanic acid, silicified microcrystalline cellulose and optionally one or more excipients;

homogenizing the obtained mixture;

sieving the homogenized mixture; and

forming tablets therefrom.

Claim 18. (Previously Presented) The process of claim 17 wherein the step of forming tablets further comprises forming tablets by direct compression.

Claim 19. (Previously Presented) The rapidly disintegrating tablet according to claim 1, wherein the tablet is formed from parts that have not undergone dry or wet granulation.

Claim 20. (Previously Presented) The rapidly disintegrating tablet according to claim 1, wherein the tablet includes up to about 1500 mg of an active substance.